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Summary 
Neutrophils, an abundant cell type at sites of inflammation, have the ability to produce a number 
of cytokines, including interleukin 1 (I1,1), I1,8, granulocyte-macrophage colony-stimulating 
factor (GM-CSF), and tumor necrosis factor ol (TNF-r  In this study, we have examined the 
ability of human neutrophils to produce the I1.-1 receptor antagonist (I1,1Ra), a 17-23-kD protein 
recently isolated and cloned from macrophages. Since I1.1Ra has been shown to inhibit both 
the in vitro and in vivo effects of II,1, its production by large numbers of tissue-invading neutrophils 
might provide a mechanism by which the effects of I1.1 are regulated in inflammation. Using 
antibodies that are specific for IblRa and a cDNA probe encoding for this protein, we were 
able to show that neutrophils constitutively produce IDIRa. However, after activation by GM- 
CSF and TNF-o~, I1.1Ra was secreted into the extracellular milieu where it constituted the major 
de novo synthesized product of activated neutrophil~ None of a large array of other potent neutrophil 
agonists were found to affect the production of IL-1Ra by neutrophils. Quantitative measurements 
by enzyme-linked immunosorbent assay revealed that intracellular I1,1Ra is in eightfold excess 
of the amount secreted in supernatants when studying nonactivated neutrophils. However, in 
GM-CSF- and TNF-ot-activated cells, this difference was reduced to values between four- and 
fivefold, as virtually all of the de novo synthesized I1.1Ra was secreted. In activated cells, the 
intracellular content of IblRa was found to be in the 2-2.5-ng/ml range per 106 neutrophils, 
whereas levels reached the 0.5-ng/ml range in supernatants. This would imply that I1.1Ra is 
produced in excess of I1.1 by a factor of at least 100, an observation that is in agreement with 
the reported amounts of I1.1Ra needed to inhibit the Proinflammatory effects of I1.1. Neutrophils 
isolated from an inflammatory milieu, the synovial fluid of patients with rheumatoid arthritis, 
were found to respond to GM-CSF and TNF-cx in terms of I1.1Ra synthesis,  indicating that 
the in vitro observations made in this study are likely to occur in an inflammatory setting in vivo. 
A  monocyte product with interleukin 1 receptor anta- 
gonist (I~LRa) activity has recently been isohted, cloned, 
and sequenced (1). Considerable interest has been generated 
by this molecule  in view of its ability to block the prolnfl~ruma- 
tory activities of II.1 both in vitro and in vivo (2, 3). Most 
studies have shown that monocytes, along with leukemia 
monocytic cell lines, produce this molecule after activation 
by a variety of stimuli. Although one report has suggested 
that neutrophils may also secrete products with 11.1 inhibi- 
tory activity (4),  no molecular characterization of this ac- 
tivity has yet been performed. It therefore remains unknown 
if neutrophils produce an 11.1 inhibitor similar to that made 
by monocytes. 
In recent years, studies from our laboratory have focused 
on investigating de novo protein synthesis and secretion by 
neutrophils after  activation by proinflammatory molecules 
(5-7). In the context of these studies, we have observed that 
a limited number of neutrophil agonists can mediate the 
nuclear-signaling events necessary to induce de novo RNA 
synthesis in this cell type (8).  Of a wide range of stimuli 
investigated, only three were found to induce significant RNA 
synthesis in neutrophils. These are GM-CSF, TNF-ol, and 
the formyhted oligopeptide FMLP. H~,  only the former 
two agonists were capable of inducing the synthesis and secre- 
tion ofa 23-kD protein, the nature of which was not identified 
at the time of our initial studies (9).  We now report that 
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1Ra produced by monocytes. We also report that of de novo 
synthesized and secreted proteins by neutrophils,  IL-1Ra is 
the major product in response to stimulation  by GM-CSF 
and TNF-c~. 
Materials  and  Methods 
Reagents.  The  following  molecules used in  this  study were 
generous gifts from the Genetics Institute (Boston, MA): recom- 
binant  human  (rh)GM-CSF,  rhlL-3, rhIL-4, and rhIL-6, rhTGF/~ 
and rh platelet-derived growth factorbb (PDGFbb) were purchased 
from  Collaborative  Research  (Bedford,  MA)  and  Bachem  Fine 
Chemicals (Torrance, CA), respectively,  whereas rhG-CSF was pur- 
chased from R & D Systems, Inc. (Minneapolis, MN). rhTNF-ol 
was a gift from Knoll Pharmaceuticals (Whippany, NJ) and rhIFN-3, 
was purchased from Chemicon International, Inc. (Temecula, CA). 
rhIL-l~  was a generous gift from Genentech Inc. (San Francisco, 
CA) and rhID8  was purchased from Upstate Biotechnology  Inc. 
(Lake Placid, NY). The formylated oligopeptide FMLP, rhC5a, and 
platelet-activating factor (PAF) were purchased from Sigma Chem- 
ical Co. (St. Louis, MO). Leukotriene B4 (LTB4) was generously 
provided by Merck-Frosst Canada (Dorval, Quebec, Canada). The 
endotoxin LPS was purchased from Gibco Laboratories (Burlington, 
Ontario,  Canada).  [3SS]Methionine, [3SS]cysteine, and  [3zP]deox- 
ycytidine triphosphate were purchased from Amersham (Oakville, 
ON, Canada). All other reagents were of  molecular biological grade 
and were purchased from the Sigma Chemical  Co. 
Neutropkil Isolation.  Neutrophils  were  isolated  from  venous 
blood obtained from normal healthy volunteers and synovial fluid 
of patients  with rheumatoid  arthritis  as previously described (5, 
6). All neutrophil preparations contained <0.2% monocytes as de- 
termined by nonspecific monoesterase staining. Viability was esti- 
mated by the trypan  blue dye exclusion procedure and found to 
be >99% in all preparations. 
Metabolic Labeling of Neutrophih.  The  neutrophils  were  sus- 
pended  at a density  of 10S/ml in methionine-  and  cysteine-free 
RPMI 1640. Labeling was performed in the presence of 0.1% FCS 
with  [3SS]methionine (1,000 Ci/mmol)  and  [3sS]cysteine (1,300 
Ci/mmol),  at a concentration of 125/zCi/ml for each hbel incubated 
at 37~  for various time periods as specified in the relevant figure 
legends. 
lmmunoisolation  oflLIRa.  Cell culture supernatants were pro- 
cessed for immunoisolation using two different sources of antibodies 
directed against IL-1Ra: (a) a cocktail ofmAbs to IL-1Ra, a generous 
gift from Dr. Ann Berger (The Upjohn Co., Kalamazoo, MI); and 
(b) a polyclonal rabbit  antibody to IL-1Ra, a generous gift from 
Dr. WiLliam Arend (University of Colorado School of Medicine, 
Denver, CO). Immunoisolation  was carried out according to the 
procedure of Davis et al.  (10). 
RNA Isolation  and Northern Blotting.  Isolation of total cellular 
RNA and Northern blots were performed as previously described 
(5). The IblRa cDNA probe used for these studies, a 1.8-kb frag- 
ment  cloned  into  the EcoRI  site of a PGEM2 plasmid,  was  a 
generous gift of Dr.  Daniel E.  Tracey (Upjohn Co.)  (11). 
Quantitative Measurement of ILIRa.  The measurement  of II~ 
1Ra was performed using an ELISA  purchased from R & D Systems, 
Inc. This immunoassay was performed as specified  by the manufac- 
turer. Statistical analyses were performed using the student's t test. 
Results 
Production  of  lLIRa by Neutrophils.  Neutrophils were stimu- 
lated with  a number  of known  neutrophil  agonists  in  the 
presence  of [3SS]methionine  and  [3SS]cysteine in  order  to 
study the effects of each agonist on the induction of de novo 
protein  synthesis  and  secretion.  SDS-PAGE was  then  per- 
formed on the incubation media obtained from treated and 
untreated neutrophils. It was observed that of all the agonists 
used in this study,  only GM-CSF and TNF-o~ induced  the 
synthesis and secretion of a 23-kD molecule by neutrophils. 
A fluorogram obtained from a typical experiment in which 
neutrophils were stimulated with either GM-CSF or TNF-c~ 
is shown in Fig. 1. The proteins secreted from nonactivated 
neutrophils  are shown in Fig.  1, lane A, whereas those ob- 
tained from GM-CSF- and TNF-ol-stimulated neutrophils are 
shown in Fig. 1, lanes B and D, respectively. Although nei- 
ther GM-CSF nor TNF-oe significantly altered general pro- 
tein synthesis in neutrophils,  it can be clearly seen that  the 
intensity of the 23-kD band, along with two slightly lower 
molecular mass bands, was significantly enhanced.  The op- 
timal concentrations for the induction of this synthesis were 
3 nM for GM-CSF and  1,000 U/ml for TNF-ot.  Optimal 
stimulating  and labeling periods were 4  h.  It was also ob- 
served that the use of a minimum of 0.1% FCS in the incu- 
bation media was sufficient for optimal induction of synthesis 
by GM-CSF and TNF-o~ (results not shown). Using a poly- 
clonal antibody to IL,1Ra, the 23-kD band along with the 
two lower molecular mass bands were immunostained both 
from the GM-CSF, and the TNF-cc-stimulated cells (Fig.  1, 
lanes C  and E,  respectively).  Similar results were obtained 
when using a cocktail of mAbs to IL-1Ra for immunoisola- 
tion. However, under the same conditions, neither II, lc~ nor 
II--13 was detected using specific mAbs directed against these 
two antigens (data not shown). The various stimuli used in 
this study are shown in Table 1. For each neutrophil agonist, 
a dose-response course was performed using concentrations 
ranging from sub- to supraoptimal levels as defined in other 
systems. Furthermore, time course studies over a 24-h period 
were also performed  with  each agonist. 
Northern blot hybridization studies were also performed 
using a cDNA probe for IL-1Ra in order to measure levels 
Figure  1.  De  novo synthesis 
and secretion  of II,1Ra by human 
neutrophils. Cells vcere  metabol- 
ically labeled with  [3sS]methio- 
nine and [3sS]cysteine  for 24 h in 
the presence  of  0.1% FCS, and the 
labeled proteins secreted  into the 
supernatants were separated by 
SDS-PAGE as described in Ma- 
terials and Methods. (A) Control 
supematant; (B) supematant  from 
GM-CSF-activated (3 nM GM- 
CSF) cells; (C) immunoisolation 
of IL-1Ra in the supernatant of 
GM-CSF-sdmulated  cells; (D) su- 
pernatant from TNF-a-acdvated 
cells (1,000 U/ml); (E) immuno- 
isolation of IL-1Ra in the super- 
natant of TNF-(x-actiwated  cens. 
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Agonists  Induction  of synthesis 
GM-CSF  Positive 
TNF-ot 
G-CSF  Negative 
IL-lfl  " 
IL-3  " 
IL-4  " 
IL-6  " 
IL-8  " 
TGF~  " 
PDGFbb  " 
IFN-y  " 
PAF  " 
C5a  " 
LTB~  " 
LPS  " 
fMet-Leu-Phe  " 
Neutrophits were activated with the agonists and metabolically labeled 
as described (see Materials and Methods). Cell supernatants were then 
analyzed by SDS-PAGE for the presence of de novo synthesized IL-1Ka. 
Experiments were repeated with cells isolated from the Peripheral blood 
of at least six normal individuals. 
of IL-1Ra mKNA in neutrophils. Kesults are shown in Fig. 
2, where it can be seen that the levels of mKNA were con- 
siderably increased in GM-CSF- and TNF-o~-activated cells 
(Fig.  2, lanes 2  and 3, respectively) over control cells (Fig. 
2, lane I), with a more pronounced effect after GM-CSF ac- 
tivation.  With a longer exposure time, a  1.9-kb band was 
also observed in unstimulated cells. Fig. 2, bottom, shows the 
photograph of the ethidium bromide-stained gel. It reveals 
the integrity of the RNA preparations along with a compar- 
ison of the total amounts loaded on the gel. 
Kinetics of  Induction of  lL.IRa mRNA Accumulation, and IIJ 
1Ra Synthesis and Secretion by Neutrophils after GM-CSF and 
TNF-ot Stimulation,  Time course studies on the influence 
of GM-CSF and TNF-ot on IL-1Ra mKNA levels in neutro- 
phils and on the induction of synthesis and secretion of IblRa 
Figure  2.  Expression of IblRa mKNA  in 
stimulated neutrophils. The cells were incubated 
under the following conditions for 4 h at 37~ 
(Lane 1) Control cells (diluent); (lane 2) GM- 
CSF-activated cells (3 nM GM-CSF); (lane 3) 
TNFcx-activated  cells (1,000 U/ml).  Northern 
blot analysis was then performed using a 321)_ 
labeled eDNA probe encoding for IblRa on 15 
#g  of total  RNA  isolated from  neutrophils. 
(Bottom) Photograph of the ethidium bromide- 
stained gel to indicate equal loading of KNA in 
each lane. 
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Figure 3.  Time course studies of the induction of IL-1Ra synthesis and 
secretion, and mKNA expression in nentrophils. Cells were treated with 
diluent, GM-CSF, or TNF-cx (as indicated in the legend to Fig. 1), for 
increasing periods of time, and at each time point, the supernatants were 
collected and subjected to SDS-PAGE analysis. Alternatively, the cells were 
collected and subjected to Northern blot analysis. (A) Demitometric scan- 
ning data obtained from a fluorogram after SDS-PAGE performed on su- 
Pematants of metabolically labeled neutrophils (/3) Densitometric scan- 
ning data obtained from a fluorogram of a Northern blot performed with 
KNA isolated from nentrophils. 
were performed. Densitometric scanning of SDS-PAGE per- 
formed with cell lysates revealed that the level de novo syn- 
thesized intracellular IblKa was maximal at  1 h  (data not 
shown), while secretion was maximal at 4 h (Fig 3 A). Similar 
analyses performed on Northern blots (Fig. 3 B) showed in- 
creased levels of IL-1Ra mKNA as early as 0.5  h, reaching 
a peak at 1 h. At 24 h, no IbRa mKNA was detectable in 
neutrophils, indicating significant degradation at this point 
in time. 
Measurement of  ll.,1Ra Production by Neutrophils.  We next 
measured the intra- and extracellular levels of IIARa using 
nonactivated and activated neutrophils. IblRa was measured 
by ELISA using cells isolated from three normal individuals, 
and the results are expressed in nanograms per milliliter/106 
neutrophils. As can be seen from Table 2, there was an eight- 
fold excess of intracellular over extraceUular IblRa in nonac- 
tivated cells and a four- to fivefold excess in activated cells, 
implying that the great majority of newly synthesized IblRa 
was being secreted. The differences between nonactivated and 
activated neutrophils with respect to intraceUular 1D1Ra levels 
were not statistically significant. In contrast, activated ceils 
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Cell lysate  Cell supernatant 
cycloheximide  cycloheximide 
-  +  -  + 
*  * 
Control  1.6  _J,  0.2  1.50  ~  0.06  0.2  _$  0.02  0.09  '_+  0.01 
GM-CSF  *  2.5  _+  0.4  1.90  _  0.11  s  0.5  _  0.06  0.1  '_+  0.01 
.  II 
TNF-o~  2.0  _  0.2  1.40  ~  0.17  0.5  _J,  0.07  0.08  ~  0.01 
IL-1Ra was measured by ELISA from neutrophil cell lysates and supernatants. Neutrophils were isolated from normal human blood and the values 
represent the mean  _+  SEM of experiments performed in duplicate on cells from three different normal donors. Statistics  were performed using the 
student's t test. 
* Not statistically different. 
t Statistically significant  at p  <0.007. 
s Statistically significant  at p  <0.001. 
II Statistically significant  at p  <:0.006. 
secreted significantly higher levels of IL-1Ra than did nonac- 
tivated cells (iv <0.007 for GM-CSF and iv <0.001 for TNF- 
c  0. We next investigated whether the increased extracellular 
levels of IblRa observed after activation were due to increased 
de novo synthesis of this molecule as opposed to increased 
secretion ofintracdlular IL-1Ra  content. To address this ques- 
tion, we activated  neutrophils with GM-CSF and TNF-oe 
in the presence or absence of the protein synthesis inhibitor, 
cycloheximide.  The results presented in Table 2 show that 
extracdlular IL-1Ra, after activation with either GM-CSF or 
TNF-oe, was markedly decreased by cycloheximide (p <0.006), 
whereas intraceUular levels were found not to be significantly 
affected. 
Level of lL.1Ra Production by Neutroivhils Relative to Other 
De Novo Synthesized and Secreted Proteins.  Upon visual in- 
spection of the fluorograms presented in Fig. 1, it can be ob- 
served that relative to the other products represented by the 
various bands seen on the fluorogram, IblRa appears as the 
major de novo synthesized and secreted neutrophil product 
in response to either GM-CSF or TNF-c~. To further illus- 
trate this, densitometric scanning studies were performed on 
the fluorograms shown in Fig.  1, lanes A, B, and D. The 
results are presented in Fig. 4. Intensity levels for all the bands 
obtained from nonactivated cells are shown in Fig.  4,  A, 
whereas Fig. 4, B and C, indicate the levels obtained from 
GM-CSF- and, TNF-oe-activated cells, respectively. It can be 
B 
23kO  i 
23  kD 
Figure 4.  Relative levels of de novo Ih-lRa synthesis and secretion com- 
pared with total protein synthesis  and secretion  by human neutrophils. 
Neutrophils were labeled and treated as described in the legend to Fig. 
1, and the proteins secreted into the supernatants were separated by SDS- 
PAGE. Densitometric scanning  data were then performed on the fluoro- 
grams obtained after SDS-PAGE. The 23-kD marker represents  IblRa. 
(A) Control cells; (B) GM-CSF-stimulated cells; (C) TNF<~-stimulated cells. 
Figure 5.  IL-1Ra  protein synthesis  and secretion,  and mRNA expres- 
sion by neutrophils isolated from the synovial fluid of a patient with rheu- 
matoid arthritis. (A) The cells were treated as described in the legend to 
Fig. 1 and the supernatants  were processed for immunoisohtion to detect 
ID1Ra.  (/3) The cells were treated as described  in the legend to Fig. 2, 
and the level of IL-1Ra mRNA expression was determined by Northern 
blot analysis. (Bottom)  Photograph of the ethidium bromide-stained gel 
used for the Northern blot indicating equal loading of RNA in each lane. 
(Lane I) Control cells; (lane 2) GM-CSF-activated cells; (lane 3) TNF-o~- 
activated  calls. 
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component of all de novo synthesized and secreted products 
of activated neutrophils. This is particularly evident in GM- 
CSF-activated  cells. 
Production of lL1Ra by Neutrophils Isolated  from the Synovial 
Fluid of Patients with Rheumatoid Arthritis.  We next wanted 
to determine whether neutrophils isolated from an inflam- 
matory milieu retained their ability to synthesize and secrete 
IL-1Ra in response to stimulation by GM-CSF and TNF-ol. 
To perform this study, we used neutrophils isolated from the 
synovial fluid of patients with rheumatoid arthritis. Neutro- 
phils were stimulated and metabolically labeled as described 
above. Immunoisolation  of IblRa from cell supernatants was 
then performed using the polydonal antibody to IL-1Re. 
Results are presented in Fig. 5 A, where it can be seen that 
there is an induction of de novo synthesis and secretion of 
IL-1Ra after GM-CSF (Fig.  5 A, lane 2) and TNF-c~ (Fig. 
5 A, lane 3) stimulation compared with nonactivated cells 
(Fig. 5 A, lane 1). Northern blots were also performed using 
RNA isolated from these cells and hybridized with the IL- 
1Ra eDNA probe. The results presented in Fig. 5 B show 
that levels of mlLNA in neutrophils are increased after GM- 
CSF (Fig. 5 B, lane 2) and TNF-ol (Fig. 5 B, lane 3) stimula- 
tion when compared with nonactivated ceils (Fig. 5 B, lane 
I). Fig.  5 B, bottom, shows a photograph of the ethidium 
bromide-stained gel used for the Northern blot. 
Discussion 
We have previously shown that GM-CSF and TNF-ol in- 
duce the de novo synthesis and secretion of a 23-kD protein 
by neutrophils in a highly sdective manner (9). In the present 
study, we have characterized  this product as the IL-1Ra. 
Measurement of the amounts of IL-1Ra associated with 
cell lysates and supernatants of neutrophils leads us to sug- 
gest that the contribution of neutrophils to the production 
of IblRa may be substantial when compared with that by 
macrophages. A recent study quantified IblRa production 
induced by GM-CSF in in vitro derived macrophages using 
ELISA  (12). Measurements were reported as the quantity 
(ng/ml) product by 0.83  x  106 macrophages. Under these 
conditions, ~40 ng/ml of IL-1Ra was associated with the 
cell lysates and 10 ng/ml was detected in the cell superna- 
tants. Although it may be inappropriate to compare our results 
(4-h incubation of neutrophils) with those of that study using 
7-d macrophage cultures, our measurements would indicate 
that macrophages produce ~20 times more IL-1Ra. If one 
is to take the example of synovial fluid from patients with 
rheumatoid arthritis, where neutrophils can outnumber mac- 
rophages by a factor of at least 20, it can be concluded that 
in the presence of GM-CSF (or TNF-cx), production of II.- 
ltLa by neutrophils may equal that by macrophages. 
Studies on de novo protein synthesis by neutrophils must 
always consider the possibility of a contribution by small 
numbers of contaminating monocytes. We have estimated that 
monocytes produce "~20 times more IblRa than neutrophils. 
Our  neutrophil preparations would therefore have  to be 
contaminated by a minimum of 5% monocytes to account 
for  all  of the  IL-1Ka that was  measured.  By  nonspecific 
monoesterase staining, contaminating monocytes never ex- 
ceeded 0.2%. 
It has been shown that IblRe must be in excess of Ibl 
to inhibit the stimulatory effects of this cytoldne (13). It there- 
fore makes physiological sense that neutrophils would pro- 
duce the amounts of IL-1Ra that they do. When analyzing 
the results of a recent study that measured II.-1 production 
by neutrophils using conditions that are highly similar to 
those used in this study (14), comparisons between IL-I~ and 
IL-1Ra production by neutrophils can be made. After 4 h of 
stimulation by TNF-o~, the cell-associated IDII3 per 106 cells 
was ,v15 pg/ml, whereas we measured 2 ng/ml of IL-1ga, 
a 130-fold excess. Again under the same conditions, the levels 
of secreted IL-113 was ,v5 vs. 500 pg/ml for IL-1ga,  a 100- 
fold excess. 
We also observed that of the de novo protein synthesis and 
secretion by neutrophils in response to activation by GM- 
CSF and TNP-ol, IL-1Ra constitutes by far the major pro- 
tein. Therefore, in terms of quantity alone, production of 
IL-1Ra by neutrophils is a major event in response to this 
type of activation. This obviously raises the issue of the bio- 
logical significance for the need of neutrophils to mount this 
relatively  massive response in terms of IL-1tLa production. 
Studies performed in vitro on the sfimulatory effects of IL-1 
on neutrophils have yielded conflicting results (15-17)  and 
will have to await further investigation before any firm con- 
clusions can be made. Interestingly, however,  IL-1 injected 
into animals leads to the accumulation of neutrophils at the 
site of injection (18), and in vivo studies on the use of IL-1Ka 
have shown that it reduces the number of tissue-invading neu- 
trophils in septic shock (3). This latter finding would be in 
agreement with the observation that IL-1ga  reduces IL-1- 
induced adhesion of neutrophils to endothelial cells (11). In 
this context, production of relatively large amounts of IL-1Ra 
by neutrophils at inflammatory sites could be of major bio- 
logical significance. 
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